The schall law firm announces the filing of class action lawsuit against lipocine inc

The schall law firm announced the filing of a class action lawsuit against lipocine inc. (lipocine) for violations of §§10(b) and 20(a) of the securities exchange act of 1934 and rule 10b-5 promulgated thereunder by the u.s. securities and exchange commission. investors who purchased the company's securities between march 27, 2019 and november 8, 2019, inclusive, are encouraged to contact the firm before january 14, 2020. according to the complaint, the company made false and misleading statements to the market. lipocine’s clinical studies of tlando did not produce results sufficient to demonstrate efficacy for the drug. due to this deficiency, the company’s third new drug application for tlando was likely to be found deficient by the fda. based on these facts, the company’s public statements were false and materially misleading throughout the class period. when the market learned the truth about lipocine, investors suffered damages.
LPCN Ratings Summary
LPCN Quant Ranking